Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
I'm PortAI, I can summarize articles.
Silexion Therapeutics Corp. will attend the 7th RNAi-Based Therapeutics Summit from January 27-29, 2026, in Boston, MA. CEO Ilan Hadar and other management will participate, and Silexion is an official partner of the summit. The company is developing SIL204, a siRNA therapy targeting mutated KRAS oncogenes, with plans for a Phase 2/3 clinical study in pancreatic cancer in mid-2026. One-on-one meetings with management can be arranged through investor relations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments